Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices

ISBN-13: 9781119881339 / Angielski / Miękka / 2022 / 128 str.

John L. Lamattina

Spis treści

Acknowledgments ixIntroduction xChapter 1 The $1000 Pill: the Fiscal Consequences of Curing Hepatitis C 1Chapter 2 Enter the Payers: Fda Approval Does Not Guarantee Commercial Success 10Chapter 3 Pandemic: mRNA Vaccines And The Race For A Cure 19Chapter 4 Federal Investment in R&d: Why the Government Does Not Deserve a Piece of Biopharma's Profits? 34Chapter 5 Insulin: the True Cost of a 100- Year- Old Drug 44Chapter 6 The Costly Alzheimer's Disease Drug: a Questionable Breakthrough 50Chapter 7 Gene Therapy: How Much Is a Life Worth? 60Chapter 8 Proving the Value of Expensive Drugs: Should We Pay For Drugs Whose Ultimate Value Is Unknown? 70Chapter 9 Generic Drugs: Built- in Cost Controls 74Chapter 10 About Those Soaring Pharma Profits: Are They Driving Healthcare Costs? 80Chapter 11 Schemes to Lower Drug Prices: the Impact of Reduced Resources on R&d 84Final Thoughts 96Index 9

O autorze

John LaMattina, PhD is the former Senior Vice President, Pfizer Inc and President, Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. Currently a Senior Partner with PureTech Health, he is the author of Drug Truths: Dispelling the Myths About Pharma R&D (2008) and Devalued and Distrusted - Can the pharmaceutical industry restore its broken image? (2013), both published by Wiley.